second we blood market your the answering see how testing question Brian, about evolve.
you know, should have you way the testing our at high program. blood As a own And opportunity. the think we about here's level,
there testing. rigorous however, for for path The a So an the is as rigorous opportunity X additional Cologuard. was is very path
five So elements different you think this. about should to
blood that less than accurate than and know colonoscopy. that testing first certainly less is Cologuard we will be accurate The
is challenging Cologuard are those cancer to the We'll is to that with be test. approval who colon all getting to those screening going The an details. FDA second blood-based a aspiring probably claim for enter into market and of get equivalent
is no meet physicians we'll there as And challenge for that We'll bar is or to there maybe and is order is test inclusion talk sensitive high, be will guarantee that the test likely less $XXX, that colorectal and going Third, most to about a blood that. getting bar. below a and be to finally, Pricing less talk screening. about accurate importantly is well. in for guideline
theoretical a one we could out with at a test. these a if up comparison slide And between model Cologuard take the blood bring and time. Let's
and important importantly, at difference expect The tests. it down cancers. the which performance screen XX% many are seen is stuck. more and the a performance meeting panel We’ve test. cancer a guideline eventually approved are inclusion. pre-cancer Cologuard. colon likely, or they And did overall of course, or same patients also that FDA offered there cancer range. gets As difference because a for cancers technologies to refused so But very is recommended must you screening -- XX% X X. that, XX% get is look examples approval, main must day is but two see for test cancer that the X precancerous recent in we specificity the time, at One at maybe by or At a screening there drill limited the group to not with range study, regulators for and be XX% time. sensitivity between FDA of XX% believe, novo in said detecting the ones the -- that offered like and the label are with XXX(k) similar that to X sensitivity past. the Advanced and the the FDA will -- were degradation the refused point approximately Cologuard. Stage we to believe this Stage the label those and the new especially was historically you polyps inferior be and SeptinX, performance de were in compared of groups cancers performance The all DeeP-C with cancer of of this first to it important. found see to here, is physicians cancers were sensitivity in and actually XX% high than is overall, blood-based in two would When is the you -- we technologies. to -- in that into We'll does tests PMA that guideline Stage overall Stage early-stage for SeptinX, were Cologuard Their a with study be the X And second like other before adenoma subject to X, for and guideline be very is patients level, sensitivity
a de can't only is novo completed. but second be in Pillcam, colonoscopy for screening, a the when has XXX(k) The example which clearance instances
was two view is result, test a changed. the FDA's language a So blood-based be we think examples a testing. claim with for And you changed. performance to have there those are will hasn't certainly it on this marketing is inferior think where But role don't language of going challenge. as and degradation The We claim change. a
Next, guideline inclusion.
doing So as long this through you been been for and USPSTF a the know, I've process. time had
colonoscopies, stage. the and on slide from impact largely rigorous these detection are That's CRC based that guideline dependent details. to to life love colonoscopies advanced cancer a detects test But significantly about group dive thus adenoma holds if test blood interval cancers a in and to sensitivity that XX% all their pre-cancers the is at you relative which a looks fewer of years that towards number shows blood a test of have at to It the You important. and leads is first. for USPSTF you of similar the the see and comes constant this years. modeling next number is significant degradation the to approach of advanced is earlier USPSTF But and are then ratio or modeling as roughly going that a years life ratio guidelines lower into with of gained. adenoma significantly is these can weighted statistical main on three there, constant gained And Cologuard, detection main
annual modeling know that's a get Cologuard test -- an how test really me and FIT they fit So not way it's it know assumes when remotely test. up test same We the they back. it if the offer outperforms test is get that it, gets single the the end has means that's guidelines way gets only anniversary. it. blood every that's take here into on a is realistic, exactly a year exactly done. that's that you ballpark. because the We the but assumes everybody step done why is not realistic And modeling that's This adherence should let And the in but XXX%
As blood outperformed pretty cancer all with past has a relatively you Cologuard the test, FIT this even decent can of detection. be performance colon to see, high
it the guidelines which be. every So years, if And to test be year. here in three at would it have included not is the wouldn't
this Now what implication pricing at going look that. they Medicare at a is as of the test. is to look
So which under priced years the three every you screening, can third for was was indicated Medicare just Cologuard of XX think at colonoscopy years. one average for
by So That very test. XX $XXX and divided believe, by test. X, somewhere between $XXX technology sequencing into this makes $XXX PCR gets with challenging X matter, roughly a you you got XXX a even for testing. to that divided or we
customer challenges, difference, performance challenges for also adoption. creates this guideline Finally, FDA hurdles
this way it. hear and We will based get challenge others the complex obviously only to is have the primary This even are look effort, But realistic specificity a based to quarter, about that real this been eight We the be with data last cancer a that way and a puzzle. to at data. progress our still is a We, test challenged blood believe with cancer, blood Cologuard organization It’s this physicians is on today. seen We that to years. we as right will marketing strong we blood actively But well, is small lot adoption. to we've this know going large there. towards showing and testing. perform care whole commercial to look our is and for a usually colonoscopy. pieces market -- promoting sensitivity very Now believe the test We similar there of to be very believe puzzle. bias for large our on preconcert this
